Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Receivables (2016 - 2025)

Iradimed (IRMD) has disclosed Receivables for 13 consecutive years, with $13.7 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 29.47% to $13.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.7 million through Dec 2025, up 29.47% year-over-year, with the annual reading at $13.7 million for FY2025, 29.47% up from the prior year.
  • Receivables for Q4 2025 was $13.7 million at Iradimed, down from $13.9 million in the prior quarter.
  • The five-year high for Receivables was $13.9 million in Q3 2025, with the low at $3.9 million in Q2 2021.
  • Average Receivables over 5 years is $10.1 million, with a median of $11.0 million recorded in 2023.
  • The sharpest move saw Receivables decreased 22.0% in 2021, then skyrocketed 158.43% in 2022.
  • Over 5 years, Receivables stood at $5.1 million in 2021, then surged by 158.43% to $13.3 million in 2022, then dropped by 7.91% to $12.2 million in 2023, then dropped by 13.65% to $10.6 million in 2024, then grew by 29.47% to $13.7 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $13.7 million, $13.9 million, and $10.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.